The GnRH antagonist Cetrorelix exhibits antiproliferative effects on endometrial cancer cells but does not act through the GnRH type 1 receptor, with a study showing that cell count was reduced to 79.8 ± 3.9% of the control. The gene discussed is GNRH1; the disease is endometrial cancer.